PD-L1 Protéines
(CD274 (PD-L1))
Involved in the costimulatory signal essential for T- cell proliferation and IFNG production in a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation by blocking cell cycle progression and cytokine production.
Filtrer les résultats:
109 Résultats
PD-L1
Origine: Humain
Hôte: Wheat germ
Recombinant
AP, AA, ELISA, WB
1 image
PD-L1
Origine: Souris
Hôte: HEK-293 Cells
Recombinant
>95 % as determined by SDS-PAGE.
Active
1 reference
PD-L1
Origine: Humain
Hôte: HEK-293 Cells
Recombinant
>90 % as determined by SDS-PAGE.
Active
PD-L1
Origine: Humain
Hôte: HEK-293 Cells
Recombinant
>95 % as determined by SDS-PAGE.
Active
PD-L1
Origine: Humain
Hôte: HEK-293 Cells
Recombinant
>90 % as determined by SDS-PAGE.
Active
PD-L1
Origine: Souris
Hôte: HEK-293 Cells
Recombinant
> 97 % by SDS-PAGE.
Active
PD-L1
Origine: Humain
Hôte: HEK-293 Cells
Recombinant
> 95 % by SDS-PAGE.
Active
PD-L1
Origine: Rat
Hôte: HEK-293 Cells
Recombinant
> 95 % by SDS-PAGE.
Active
PD-L1
Origine: Humain
Hôte: HEK-293 Cells
Recombinant
>95 % (SDS-PAGE)
Active
PD-L1
Origine: Humain
Hôte: HEK-293 Cells
Recombinant
>95 % (SDS-PAGE)
Active
PD-L1
Origine: Humain
Hôte: HEK-293 Cells
Recombinant
> 95 % as determined by Bis-Tris PAGE,> 95 % as determined by HPLC
Active
PD-L1
Origine: Humain
Hôte: HEK-293 Cells
Recombinant
> 95 % as determined by Bis-Tris PAGE,> 95 % as determined by HPLC
Active
PD-L1
Origine: Humain
Hôte: HEK-293 Cells
Recombinant
>95 % , as determined by SDS-PAGE and HPLC
PD-L1
Origine: Chien
Hôte: HEK-293 Cells
Recombinant
The purity of the protein is greater than 95 % as determined by SDS-PAGE and Coomassie blue staining.
ScA, AM, ADA, IA
PD-L1
Origine: Chien
Hôte: HEK-293 Cells
Recombinant
The purity of the protein is greater than 95 % as determined by SDS-PAGE and Coomassie blue staining.
ScA, AM, ADA, IA
PD-L1
Origine: Humain
Hôte: HEK-293 Cells
Recombinant
The purity of the protein is greater than 95 % as determined by SDS-PAGE and Coomassie blue staining.
ScA, AM, ADA, IA
PD-L1
Origine: Humain
Hôte: HEK-293 Cells
Recombinant
The purity of the protein is greater than 95 % as determined by SDS-PAGE and Coomassie blue staining.
ScA, AM, ADA, IA
PD-L1
Origine: Chien
Hôte: HEK-293 Cells
Recombinant
The purity of the protein is greater than 95 % as determined by SDS-PAGE and Coomassie blue staining.
ScA, AM, ADA, IA
PD-L1
Origine: Souris
Hôte: Human Cells
Recombinant
> 95 % as determined by reducing SDS-PAGE.
PD-L1
Origine: Humain
Hôte: Human Cells
Recombinant
> 95 % as determined by reducing SDS-PAGE.
Dernières publications pour nos PD-L1 Protéines
: "Focused Ultrasound-Enhanced Delivery of Intranasally Administered Anti-Programmed Cell Death-Ligand 1 Antibody to an Intracranial Murine Glioma Model." dans: Pharmaceutics, Vol. 13, Issue 2, (2021) (PubMed).
: "PD-L1 aptamer isolation via Modular-SELEX and its applications in cancer cell detection and tumor tissue section imaging." dans: The Analyst, Vol. 146, Issue 9, pp. 2910-2918, (2021) (PubMed).
: "Blocking interaction between SHP2 and PD-1 denotes a novel opportunity for developing PD-1 inhibitors." dans: EMBO molecular medicine, Vol. 12, Issue 6, pp. e11571, (2020) (PubMed).
: "Prophylactic In Vivo Hematopoietic Stem Cell Gene Therapy with an Immune Checkpoint Inhibitor Reverses Tumor Growth in Syngeneic Mouse Tumor Models." dans: Cancer research, Vol. 80, Issue 3, pp. 549-560, (2020) (PubMed).
: "Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. ..." dans: Nature medicine, Vol. 26, Issue 5, pp. 732-740, (2020) (PubMed).
: "Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity." dans: Cancer immunology, immunotherapy : CII, (2020) (PubMed).
: "In Vitro Assays to Study PD-1 Biology in Human T Cells." dans: Current protocols in immunology, Vol. 130, Issue 1, pp. e103, (2020) (PubMed).
: "Comprehensive in vitro characterization of PD-L1 small molecule inhibitors. ..." dans: Scientific reports, Vol. 9, Issue 1, pp. 12392, (2019) (PubMed).
: "Enhanced Expression of PD-L1 on Microglia After Surgical Brain Injury Exerts Self-Protection from Inflammation and Promotes Neurological Repair." dans: Neurochemical research, Vol. 44, Issue 11, pp. 2470-2481, (2019) (PubMed).
: "A small-sized protein binder specific for human PD-1 effectively suppresses the tumour growth in tumour mouse model." dans: Journal of drug targeting, pp. 1-9, (2019) (PubMed).
: "PD-L1 aptamer isolation via Modular-SELEX and its applications in cancer cell detection and tumor tissue section imaging." dans: The Analyst, Vol. 146, Issue 9, pp. 2910-2918, (2021) (PubMed).
: "Blocking interaction between SHP2 and PD-1 denotes a novel opportunity for developing PD-1 inhibitors." dans: EMBO molecular medicine, Vol. 12, Issue 6, pp. e11571, (2020) (PubMed).
: "Prophylactic In Vivo Hematopoietic Stem Cell Gene Therapy with an Immune Checkpoint Inhibitor Reverses Tumor Growth in Syngeneic Mouse Tumor Models." dans: Cancer research, Vol. 80, Issue 3, pp. 549-560, (2020) (PubMed).
: "Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. ..." dans: Nature medicine, Vol. 26, Issue 5, pp. 732-740, (2020) (PubMed).
: "Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity." dans: Cancer immunology, immunotherapy : CII, (2020) (PubMed).
: "In Vitro Assays to Study PD-1 Biology in Human T Cells." dans: Current protocols in immunology, Vol. 130, Issue 1, pp. e103, (2020) (PubMed).
: "Comprehensive in vitro characterization of PD-L1 small molecule inhibitors. ..." dans: Scientific reports, Vol. 9, Issue 1, pp. 12392, (2019) (PubMed).
: "Enhanced Expression of PD-L1 on Microglia After Surgical Brain Injury Exerts Self-Protection from Inflammation and Promotes Neurological Repair." dans: Neurochemical research, Vol. 44, Issue 11, pp. 2470-2481, (2019) (PubMed).
: "A small-sized protein binder specific for human PD-1 effectively suppresses the tumour growth in tumour mouse model." dans: Journal of drug targeting, pp. 1-9, (2019) (PubMed).
Pseudonymes pour PD-L1 Protéines
CD274 molecule (CD274) ProtéinesCD274 antigen (Cd274) Protéines
programmed cell death 1 ligand 2 (PDCD1LG2) Protéines
CD274 molecule (Cd274) Protéines
A530045L16Rik Protéines
B7-H Protéines
B7H1 Protéines
B7h1 Protéines
PD-L1 Protéines
PDCD1L1 Protéines
Pdcd1l1 Protéines
PDCD1LG1 Protéines
Pdcd1lg1 Protéines
PDL1 Protéines
Pdl1 Protéines
RGD1566211 Protéines
Avez-vous cherché autre chose?
- PCYT2 Protéines
- PCYOX1L Protéines
- PCYOX1 Protéines
- PCTP Protéines
- PCSK7 Protéines
- PCSK5 Protéines
- PCSK4 Protéines
- PCSK2 Protéines
- PCSK1N Protéines
- PCSK1 Protéines
- PCP4 Protéines
- Pcp2 Protéines
- PCOLCE2 Protéines
- PCOLCE Protéines
- PCNP Protéines
- PCMTD1 Protéines
- PCMT1 Protéines
- PCM1 Protéines
- PCIF1 Protéines
- PCID2 Protéines
- PDAP1 Protéines
- PDCD2 Protéines
- PDCD2L Protéines
- PDCD5 Protéines
- PDCD6 Protéines
- PDCD7 Protéines
- PDCL2 Protéines
- PDCL3 Protéines
- PDE10A Protéines
- PDE11A Protéines
- PDE12 Protéines
- PDE1A Protéines
- PDE1B Protéines
- PDE1C Protéines
- PDE2A Protéines
- PDE3A Protéines
- PDE4A Protéines
- PDE4B Protéines
- PDE4C Protéines
- PDE4D Protéines
Vous êtes ici:
